# Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD

> **NCT00684853** · PHASE2 · UNKNOWN · sponsor: **Federal University of São Paulo** · enrollment: 50 (estimated)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** vetaporfin

## Key facts

- **NCT ID:** NCT00684853
- **Lead sponsor:** Federal University of São Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-11
- **Primary completion:** 2008-05
- **Final completion:** —
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2008-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684853, "Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00684853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*